Free tool
FAERS Monitor: Draximage Dtpa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018511 or its brand name (Draximage Dtpa, Technetium Tc-99m Pentetate Kit). Reports on generic versions are filed under their own applications.
Reports
13
Serious
3
23% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6
- dyspnoea2
- product ineffective2
- blood pressure increased1
- cns ventriculitis1
- confusional state1
- erythema1
- feeling hot1
- foetal heart rate deceleration abnormality1
- headache1
- hypersensitivity1
- incorrect route of product administration1
- lethargy1
- malaise1
- meningitis chemical1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,146 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| meningitis chemical | 1 | 7395.2 | 1119.7 | 1,839 |
| cns ventriculitis | 1 | 4983.2 | 755.7 | 1,241 |
| product ineffective | 2 | 4131.5 | 1152.4 | 4,633 |
| foetal heart rate deceleration abnormality | 1 | 2297.2 | 348.9 | 573 |
| incorrect route of product administration | 1 | 94.4 | 14.4 | 23 |
| lethargy | 1 | 28.1 | 4.3 | 6 |
| feeling hot | 1 | 26.4 | 4.0 | 6 |
| blood pressure increased | 1 | 10.6 | 1.6 | 2 |
| confusional state | 1 | 10.0 | 1.5 | 2 |
| hypersensitivity | 1 | 8.7 | 1.3 | 1 |
| erythema | 1 | 7.9 | 1.2 | 1 |
| drug ineffectiveSignal | 6 | 7.4 | 4.1 | 29 |
| dyspnoea | 2 | 5.7 | 1.6 | 4 |
| malaise | 1 | 3.7 | 0.6 | 0 |
| headache | 1 | 2.6 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.